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Transition of peritoneal mesothelial cells to a mesenchymal
phenotype plays an integral role in the angiogenic
and fibrotic changes seen in the peritoneum of patients
receiving long-term peritoneal dialysis. While signaling by
transforming growth factor (TGF)-b through Smad proteins
likely causes these changes, it is possible that non-Smad
pathways may also play a role. Here, we found that
Smad3-deficient mice were protected from peritoneal fibrosis
and angiogenesis caused by adenovirus-mediated gene
transfer of active TGF-b1 to mesothelial cells; however,
mesothelial transition occurred in this setting, suggesting
involvement of non-Smad mechanisms. The phosphatidyl
inositol 3 kinase (PI3K) target, Akt, was upregulated in both
Smad-deficient and wild-type mice after exposure to TGF-b1.
In vivo inhibition of the mammalian target of rapamycin
(mTOR) by rapamycin completely abrogated the transition
response in Smad3-deficient but not in wild-type mice.
Rapamycin blocked nuclear localization of b-catenin
independent of glycogen synthase kinase 3b activity.
Further, in Smad3-deficient mice rapamycin reduced
the expression of a-smooth muscle actin, which is an
epithelial-to-mesenchymal transition-associated gene.
Hence, we conclude that TGF-b1 causes peritoneal injury
through Smad-dependent and Smad-independent pathways;
the latter involves redundant mechanisms inhibited by
rapamycin, suggesting that suppression of both pathways
may be necessary to abrogate mesothelial transition.
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During long-term peritoneal dialysis treatment, the peri-
toneal membrane undergoes structural and functional
alterations. The structural alterations include fibrosis and
angiogenesis of the peritoneal tissue.1 The functional changes
results in an increased rate of solute transport across the
peritoneal membrane and ultrafiltration dysfunction. These
changes are associated with adverse outcome, technique
failure, and death.2 We have previously shown that trans-
forming growth factor (TGF)-b1 induces transition of
the lining peritoneal mesothelial cells to myofibroblasts.3
This cellular transition is observed in patients in peritoneal
dialysis patients4 and is an integral component of both
fibrosis and angiogenesis.5
TGF-b binds to its receptors to activate the Smad family
of signaling proteins.6 Upon ligand binding and TGF-b1
receptor activation, phosphorylation of receptor-regulated
Smad2 and Smad3 occurs, which leads to the formation of
complexes with Smad4. These complexes then translocate
into the nucleus, in which they regulate expression of TGF-b-
responsive genes.
TGF-b1 signaling through Smad3 seems to be a crucial
element in the signal transduction pathways involved in
wound healing and fibrosis. Smad3/ mice were protected
against radiation-induced fibrosis of the skin,7 renal inter-
stitial fibrosis,8 and TGF-b1-induced pulmonary fibrosis.9
TGF-b1 also induces epithelial-to-mesenchymal transition
(EMT), a process involved in many physiological and
pathological processes.10 EMT seems to be an integral
component of injury response and tissue fibrosis in a variety
of organs, and inhibition of EMT ameliorates fibrosis;11
however, it is uncertain whether EMT is necessary for organ
fibrosis.12 EMT involves a series of distinct processes,
including loss of cell polarity, loss of intercellular adhesion
and epithelial markers, cytoskeletal reorganization and
expression of mesenchymal markers, extracellular matrix
degradation, and cellular mobilization.13 The role of Smad3
signaling in TGF-b1-induced EMT is controversial. Some
studies have invoked a requirement for Smad3 signaling in
the induction of EMT,8,14,15 whereas others have found a
modified EMT to occur in the absences of Smad3.16,17
Clearly, other non-Smad pathways are involved in TGF-b1-
induced EMT.18,19
http://www.kidney-international.org o r ig ina l a r t i c l e
& 2010 International Society of Nephrology
Received 8 June 2009; revised 19 August 2009; accepted 22 September
2009; published online 2 December 2009
Correspondence: Peter J. Margetts, Department of Medicine, McMaster
University, Division of Nephrology, St Joseph’s Hospital, 50 Charlton Avenue
East, Hamilton, Ontario, Canada L8P 4A6.
E-mail: margetts@mcmaster.ca
Kidney International (2010) 77, 319–328 319
Among the potential non-Smad mechanisms involved
in EMT, the phosphatidyl inositol 3 kinase (PI3K)/Akt and
wnt/b-catenin pathways have been extensively studied,20,21
and we have focused on these pathways in our experimental
model. PI3K is activated by several growth factors including
TGF-b.22 PI3K activates Akt through phosphorylation at
serine 473 (p-Akt). p-Akt has multiple actions including
upregulation of the mammalian target of rapamycin
(mTOR).23 Through the downstream kinase p70 S6, mTOR
modulates mRNA translation and protein expression and is
involved in cell growth and proliferation.24 Wnt signaling
leads to the downstream suppression of glycogen synthase
kinase (GSK)-3b and accumulation of b-catenin that
translocates to the nucleus and exerts an effect as a
transcriptional regulator.25
RESULTS
Smad3/ mice are protected from AdTGF-b1-induced
fibrosis and angiogenesis
Smad3þ /þ and Smad3/ mice received an intraperitoneal
injection of an adenovirus expressing TGF-b1 (AdTGF-b1),
vascular endothelial growth factor (AdVEGF), or control adeno-
virus (AdDL). AdDL did not induce any observable change in
the peritoneum at day 7 and there were no differences bet-
ween Smad3þ /þ (Figure 1a) and Smad3/ mice (Figure 1b).
We observed significant histological changes in the parietal
peritoneal tissue of Smad3þ /þ mice treated with TGF-b1
(Figure 1c). The obvious changes included a fibroproliferative
response with increased submesothelial thickness, increased
cellularity of the submesothelium, and angiogenesis. Quantita-
tive histology of von-Willebrand factor-stained sections
(Figure 2) showed that maximum submesothelial thickness in
Smad3þ /þ animals occurred at day 14 and started to decrease
by day 21 (Figure 2a). Submesothelial vascularization also in-
creased in Smad3þ /þ mice treated with AdTGF-b1 (Figure 2b).
These changes were maximal at day 14 and declined there-
after. In contrast, Smad3/ mice treated with TGF-b1 showed
only minor histological changes in the peritoneal membrane
(Figure 1d) with no significant submesothelial thickening or
angiogenic response (Figure 2a and b).
To show that the angiogenic difference between Smad3þ /þ
and Smad3/ mice was TGF-b1 specific, we also assessed the
response to a different angiogenic signal. Both Smad3þ /þ and
Smad3/ mice showed robust but transient peritoneal
angiogenesis in response to AdVEGF (Figures 1e, f, and 2b).
Smad3/ mice do not show changes in fibrogenic and
angiogenic gene expression after AdTGF-b1 infection
We confirmed that Smad3/ mice do not develop fibrosis in
response to TGF-b1 (Figure 2). Total birefringent area (red þ
green) from picrosirius red-stained sections indicates total
collagen, whereas the green birefringent area is suggestive of
new collagen deposition.26 There was a significant increase in
the amount of existing (Figure 2c) and newly deposited
collagen (Figure 2d) in Smad3þ /þ mice treated with
AdTGF-b1. There was a minor increase in collagen deposi-
tion in Smad3/ animals treated with AdTGF-b compared
with control adenovirus-treated animals. This was significant
at day 7 for total collagen only (Figure 2c).
We extracted RNA from the parietal peritoneal membrane,
as has been previously described,3 and carried out quantitative
reverse transcriptase-polymerase chain reaction for fibrosis-
associated gene expression. There was a significant transient
increase in plasminogen activator inhibitor 1 gene expression
in Smad3þ /þ animals treated with AdTGF-b1 (Figure 2e).
These mice also showed a progressive increase in VEGF gene
expression after infection with AdTGF-b1 (Figure 2f).
Smad3/ mice treated with AdTGF-b1 showed no significant
increases in either plasminogen activator inhibitor 1 or VEGF.
Smad3þ /þ and Smad3/ mice develop EMT in response
to TGF-b1
Smad3þ /þ mice developed EMT as expected after over-
expression of TGF-b1. In Figure 3, there is evidence of
Figure 1 |Histology of the anterior abdominal wall 7 days
after intraperitoneal adenovirus administration. (a) Smad3þ /þ
and (b) Smad3/ mice treated with control adenovirus (AdDL)
show normal peritoneal histology with a mesothelial cell layer
(thin arrow), a thin submesothelial layer (thick arrow) overlying
the abdominal musculature. (c) Smad3þ /þ mice treated with
adenovirus expressing transforming growth factor-b1 (AdTGF-b1)
show a strong fibroproliferative response (arrow). (d) Smad3/
mice treated with AdTGF-b1 show a moderate proliferative
response without significant fibrosis or angiogenesis. (e) Smad3þ /þ
and (f) Smad3/ mice treated with adenovirus expressing
vascular endothelial growth factor (AdVEGF) show a similar
angiogenic response (thick arrows). Masson’s trichrome stain,
original magnification  200.
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epithelial cells (cytokeratin positive) that co-express
a-smooth muscle actin (SMA). At 4 days after infection,
these cells exist in a single superficial mesothelial cell
layer (Figure 3a–c). Smad3/ mice treated with AdTGF-b1
showed similar but attenuated changes to those observed
in the Smad3þ /þ animals (Figure 3d–f).
By day 7, cytokeratin-positive cells are observed in the
submesothelial zone of Smad3þ /þ mice treated with
AdTGF-b1 (Figure 4a–c, Supplementary Figure S2), both
dual and single labeled. This is suggestive of an invasive
phenotype of these cells undergoing transition. Again, these
changes were observed in the Smad3/ mice but in an
attenuated form (Figure 4d–f, Supplementary Figure S2).
There were no changes suggestive of EMT observed in either
Smad3þ /þ or Smad3/ animals treated with the control
adenovirus (Figures 3g–i and 4g–i).
We analyzed the expression of EMT-associated genes.
We observed a significant and similar increase in a-SMA gene
expression in Smad3þ /þ animals treated with AdTGF-b1
(Figure 5a), with no differences between the Smad3þ /þ and
Smad3/ mice. Snail, a zinc-finger regulatory protein impor-
tant in EMT,27 was induced by TGF-b1 in Smad3þ /þ animals
(Figure 5b). Snail mRNA was significantly higher in AdTGF-
b1-treated Smad3þ /þ animals compared with Smad3/
animals. Despite this difference in SNAIL expression, we
observed a markedly lower level of E-cadherin protein that
was similarly suppressed in both Smad3/ and Smad3þ /þ
mice treated with AdTGF-b1 compared with control
adenovirus-treated animals (Figure 5d).
EMT was quantified by counting the number of dual-
labeled cells in the peritoneal tissue (Figure 5e) and
by studying the amount of EMT-related cellular invasion
(Figure 5f). EMT occurred, but at a significantly lower
frequency in the Smad3/ mice treated with AdTGF-b1
compared with the Smad3þ /þ mice. Cellular invasion was
prevalent in the Smad3þ /þ mice, but was transient in the
Smad3/ mice treated with AdTGF-b1.
Rapamycin blocks EMT response in Smad3/ mice
After transfer of TGF-b1 to the peritoneum of Smad3þ /þ
and Smad3/ mice, we treated them with the mTOR
inhibitor rapamycin or vehicle by daily gavage. Rapamycin
almost completely blocked evidence of EMT response to
TGF-b1 in the Smad3/ mice (Figure 6). Invasive dual-
labeled cells were observed in the Smad3/ animals treated
with AdTGF-b1 (Figure 6a–c), but only occasional dual-
labeled cells were observed in the Smad3/ animals treated
with rapamycin. We quantified these cells (Figure 6g) and
showed that rapamycin significantly reduced the EMT res-
ponse in Smad3/mice but had no effect on the Smad3þ /þ
mice. Animals treated with rapamycin and AdTGF-b1 had
similar peritoneal effluent levels of TGF-b1 compared to
vehicle-treated animals (Supplementary Figure S1). There
were very rare dual-labeled cells observed in the Smad3þ /þ
animals exposed to the control adenovirus. There was no
observed EMT-related submesothelial invasion in the
Smad3þ /þ animals treated with AdDL or Smad3/ mice
treated with rapamycin.
Akt activity is increased by TGF-b1. To measure PI3K/Akt
pathway activation, serine 473 phosphorylation of Akt was
assessed using western blot (Figure 7b). Overall, TGF-b1
increased p-Akt concentration in the peritoneal tissue
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Figure 2 |Quantification of submesothelium thickness and
vascularization. (a) Adenovirus expressing transforming growth
factor-b1 (AdTGF-b1)-induced submesothelial thickening is Smad3
dependent. Smad3þ /þ animals treated with AdTGF-b1 showed
increased submesothelial thickening compared with control
adenovirus (AdDL)-treated animals and with Smad3/ animals
treated with AdTGF-b1. (b) Angiogenesis measured as vessels per
millimeter length of peritoneum. Animals treated with adenovirus
expressing vascular endothelial growth factor (AdVEGF) are
included in this analysis. AdTGF-b1 induced angiogenesis
in Smad3þ /þ but not in Smad3/ animals. VEGF induced
significant but transient angiogenesis in both Smad3þ /þ
and Smad3/ animals. (c) Sections were stained with picrosirius
red and evaluated using polarized light microscopy. Total
birefringence (red þ green area) represents total collagen and
(d) green birefringent area represents newly deposited collagen.
Smad3þ /þ animals treated with AdTGF-b1 showed more total
and new collagen deposition compared with control AdDL-
treated animals and Smad3/ animals treated with AdTGF-b1.
(c) There was a transient but significant increase in total
collagen deposited at day 7 in the Smad3/ animal treated
with AdTGF-b1 compared with control AdDL-treated animals.
mRNA was extracted from parietal peritoneal tissues and analyzed
using quantitative real-time polymerase chain reaction. There was
a strong upregulation of (e) plasminogen activator inhibitor 1
(PAI-1) and (f) VEGF in Smad3þ /þ mice exposed to TGF-b1.
Smad3/ mice did not show a significant change in the
expression of these genes.
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(Po0.001, AdTGF-b1 vs AdDL). In AdTGF-b1-treated
animals, p-Akt was increased in Smad3/ mice compared
with Smad3þ /þ mice (P¼ 0.011). Rapamycin treatment also
increased p-Akt in AdTGF-b1-treated mice (P¼ 0.024).
Smad3/ mice infected with AdTGF-b1 and treated with
rapamycin showed the greatest increase in p-Akt.
Rapamycin increased GSK-3b phosphorylation
GSK-3b is constitutively active and is inactivated through
serine 9 (Ser9) phosphorylation. Akt is known to phospho-
rylate GSK-3b and we found that Smad3/ mice treated
with AdTGF-b1 and rapamycin, which showed the greatest
Akt activation, also showed the highest level of Ser9 GSK-3b
phosphorylation (Figure 7c). GSK-3b protein concentration
and Ser9 phosphorylation were not significantly regulated in
Smad3þ /þ mice.
Rapamycin blocks b-catenin protein, nuclear accumula-
tion, and a-SMA expression. Overall, when both Smad3/
and Smad3þ /þ mice are combined, rapamycin significantly
downregulated total b-catenin protein concentration
(P¼ 0.02; Figure 7d). We further analyzed b-catenin protein
expression and cellular localization using immunohisto-
chemistry (Figure 8). There was an increase in b-catenin
in the peritoneal tissue of Smad3/ (Figure 8a and b) and
Smad3þ /þ (Figure 8g and h) mice treated with AdTGF-b1
compared with control adenovirus-treated animals (Figure 8e
and f). Rapamycin treatment reduced b-catenin expres-
sion and inhibited nuclear localization in both Smad3/
(Figure 8c and d) and Smad3þ /þ (Figure 8i and j) mice
treated with AdTGF-b1.
Gene (Figure 7e) and protein (Figure 6) expression of
a-SMA was blocked by rapamycin in the animals treated
with Smad3/. Rapamycin had no effect on a-SMA gene
expression in the Smad3þ /þ mice.
DISCUSSION
In these experiments, we analyzed the signaling pathways
involved in peritoneal injury, EMT, and peritoneal fibrosis
after exposure to the profibrotic cytokine TGF-b1. We obser-
ved that Smad3/ mice are protected from fibrosis, angio-
genesis, and the associated peritoneal membrane functional
changes. The lack of extracellular matrix expansion in the
Figure 3 | Sections of parietal peritoneal tissue were stained for cytokeratin (green) and a-SMA (red) with 4,6-diamidino-2-phenylindole
(DAPI) counterstaining. At 4 days after infection with adenovirus expressing transforming growth factor-b1 (AdTGF-b1), Smad3þ /þ mice
showed mesothelial cells that stained for both cytokeratin and a-smooth muscle actin (a-SMA; a–c, thin arrows) along with mesothelial
cells without evidence of epithelial-to-mesenchymal transition (thick arrows). Smad3/ animals (d–f) showed a similar response at this
time point with AdTGF-b1-induced dual-labeled cells (thin arrows) and non-transformed mesothelium (thick arrows). (g–i) Control adenovirus-
treated Smad3þ /þ animals did not show any cellular transition or migration. Original magnification  200.
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Smad3/ mice after intraperitoneal administration of
AdTGF-b1 is in agreement with a study of lung injury by
Bonniaud et al.9 We have previously shown that TGF-b1
overexpression leads to an increased expression of VEGF in
the peritoneum.28 This process is clearly Smad3 dependent,
as there was no increase in VEGF mRNA in the Smad3/
mice treated with AdTGF-b1 (Figure 2f). We also showed
that the lack of angiogenic response is specific for TGF-b1
as both Smad3/ and Smad3þ /þ mice have robust but
transient angiogenic responses to adenovirus-mediated gene
transfer of VEGF (Figures 1 and 2).
EMT is an integral element of wound repair, as is
elaboration of extracellular matrix and angiogenesis. We
found that EMToccurred in the absence of significant fibrosis
in the Smad3/ mice treated with AdTGF-b1, suggesting
that EMT and fibrosis are independent events and fibrosis
requires further Smad3-dependent process to occur. The
EMT response in the Smad3/ mice was attenuated and the
cellular invasion was transient. This suggests that Smad3 is
important for some aspects of persisting EMT, and Banh
et al.17 have suggested that Smad3 may inhibit apoptosis
of newly generated myofibroblasts. Further, we show that
inhibition of mTOR signaling completely inhibited the EMT
response in Smad3/ mice but had no effect on EMT in
Smad3þ /þ . Specifically, in Smad3/ mice, rapamycin
blocked a-SMA expression and evidence of cellular transi-
tion. Rapamycin also eliminated cellular invasion, which
is a feature of TGF-b1-induced EMT in this peritoneal
injury model.3
Smad3 signaling has been implicated in TGF-b-induced
EMT in several in vitro studies.15,29 However, the evidence for
a role of Smad3 in EMT in vivo is contradictory. In a model
of unilateral ureteric obstruction, Sato et al.8 found that
Smad3/ mice were protected against EMT and tubuloin-
terstitial fibrosis. Similarly, in a study of ocular lens
epithelium, Saiko et al.14 found that EMT did not occur in
the absence of Smad3. In contrast, Banh et al.17 found an
attenuated EMT response in the lens epithelium of animals
overexpressing TGF-b1 on a Smad3-null background.17 In
our experiments with overexpression of TGF-b1 in the
Figure 4 | Sections of parietal peritoneal tissue taken at day 7 were stained for cytokeratin (green) and a-smooth muscle actin
(a-SMA; red) with 4,6-diamidino-2-phenylindole (DAPI) counterstaining. (a–c) In Smad3þ /þ animals, transforming growth factor-b1
(TGF-b1) induced cellular transition and submesothelial invasion with both dual-labeled (thin arrows) and cytokeratin-labeled (thick arrows)
cells intermingled in the submesothelial zone. (d–f) Smad3/ mice showed similar but attenuated epithelial-to-mesenchymal transition
responses 7 days after treatment with adenovirus expressing TGF-b1 (AdTGF-b1). (g–i) Control adenovirus-treated Smad3/ animals
did not show any cellular transition or migration. Original magnification  200.
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peritoneum, E-cadherin was suppressed in both Smad3þ /þ
and Smad3/ mice. Snail gene expression was mostly Smad3
dependent. Snail is a key regulator of E-cadherin gene expres-
sion and our data suggest that other factors are involved in
E-cadherin downregulation in the Smad3/ mice.
The novel and most important finding from our study is
that there seems to be a separate but interacting pathway
involved in TGF-b1-induced EMTand that dual inhibition of
Smad3 and mTOR is necessary to completely abrogate the
EMTresponse. Our observation that rapamycin did not affect
EMT in the Smad3þ /þ mice is supported by recent work by
Lamouille et al.20. They found that TGF-b activated mTOR,
and mTOR inhibition affected cell growth, invasion, and
migration but did not affect the overall EMT response. Other
in vitro work supports an inhibiting effect of rapamycin on
EMT in peritoneal mesothelial30 or renal tubular epithelial
cells.31 How the proposed switch to an alternate PI3K/Akt
EMT pathway in the absence of Smad3 is made is not clear.
There is evidence that PI3K interacts with Smad3, but in a
positive manner, so that PI3K or Akt can activate Smad3.20,22
The possibility that PI3K activity is increased in the absence
of Smad3 has not been observed previously. This suggests
that Smad3 may have an inhibitory effect on PI3K/Akt
signaling (Figure 9).
Rapamycin is known to inhibit mTOR complex 1 that is
activated downstream by the PI3K/Akt pathway.23 We found
a significant increase in Akt phosphorylation after TGF-b1
exposure in both Smad3þ /þ and Smad3/ mice in keeping
with previous observations.22 We also found that Akt phos-
phorylation was increased in rapamycin-treated animals. This
is in agreement with recent observations that mTOR complex
1 negatively feeds back to inhibit Akt activation and rapamy-
cin inhibits this negative-feedback mechanism (Figure 9).32,33
The regulation of GSK-3b is complex. GSK-3b is an
inhibitory kinase that is constitutively present and targets
a variety of proteins for ubiquitination. GSK-3b is involved
in the control of glycogen metabolism, cell cycle, mobility,
and survival.34 Akt is able to directly phosphorylate GSK-3b
at Ser9 and inhibit its kinase activity.23 GSK-3b is also
phosphorylated and inhibited by the canonical wnt signaling
pathway,35 and recently, p70 S6 kinase, a downstream effector
of mTOR complex 1, has been shown to inhibit GSK-3b.33,34
Interestingly, rapamycin has been shown to increase GSK-3b
activity through a mechanism independent of Ser9 phospho-
rylation.24 GSK-3b has multiple targets including b-catenin.
b-catenin forms a scaffold with E-cadherin at the inner cell
membrane and is quickly marked for degradation in the
cytosol through phosphorylation by GSK-3b. If GSK-3b
is inhibited, primarily through Akt or wnt signaling, then
b-catenin will accumulate, transport to the nucleus, and
initiate transcription of genes involved in cell growth, proli-
feration, and survival.36
Although inhibition of GSK-3b is the classic pathway
for cytoplasmic b-catenin accumulation and its nuclear
translocation, there is evidence that b-catenin can accumu-
late even in the presence of functionally active GSK-3b.34
Interestingly, several recent studies have shown that b-catenin
expression37,38 and nuclear localization37 are directly inhibi-
ted by rapamycin. The exact mechanism of this inhibition
remains unclear. In the Smad3/ animals, Smad2 is still
functional39 and recently, Smad2 has been shown to directly
interact with b-catenin in the nucleus.40 Persisting Smad2
activity in the Smad3/ mice may therefore be having a role
in the b-catenin-dependent EMT that we have observed.
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Figure 5 | Epithelial-to-mesenchymal transition occurs in
the absence of Smad3. Quantitative reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis of (a) a-smooth
muscle actin (a-SMA) and (b) SNAIL. Transforming growth
factor-b1 (TGF-b1) induced a significant increase in a-SMA
gene expression in Smad3þ /þ animals compared with control
treated animals. (b) TGF-b1 also induced a significant increase in
SNAIL gene expression in Smad3þ /þ mice. (c, d) E-cadherin
protein expression is downregulated in mice treated with
adenovirus expressing TGF-b1 (AdTGF-b1). A representative
western blot is shown in (c) and quantified in (d), which confirmed
a significant downregulation in both Smad3þ /þ and Smad3/
mice treated with AdTGF-b1. (e) Epithelial-to-mesenchymal
transition (EMT) was quantified by counting the number of dual-
labeled a-SMA/cytokeratin-positive cells in the peritoneal tissues.
Both Smad3/ and Smad3þ /þ had a quantifiable increase in
dual-labeled cells, and Smad3þ /þ mice had significantly more
dual-labeled cells than Smad3/ mice treated with AdTGF-b1.
(f) The degree of cellular invasion was also quantified. Smad3þ /þ
mice treated with AdTGF-b1 had prolonged evidence of
submesothelial invasion with dual-labeled cells, whereas
Smad3/ mice treated with AdTGF-b1 showed only transient
EMT-associated invasion. No evidence of migration of dual-
labeled cells was observed in the control adenovirus-treated
animals.
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Our observations concerning the effects of rapamycin in
TGF-b1-induced EMT in Smad3/ mice are in agreement
with these previous studies. Rapamycin increased Akt
activation through inhibition of the mTOR complex 1
negative-feedback regulation (Figure 9). The increased Akt
activation leads to increased GSK-3b Ser9 phosphorylation
and inactivation. This should result in b-catenin accumula-
tion and nuclear localization, especially in the rapamycin-
treated Smad3/ animals, in which Akt activation was most
profound. However, contrary to these expectations, b-catenin
accumulation was significantly inhibited in our experiments,
and we hypothesize that this may be a direct action of
rapamycin.37 Alternatively, rapamycin may indirectly inhibit
b-catenin through GSK-3b activation,24 through a Smad2
mechanism, or through mTOR/p70 S6 kinase (Figure 9).
We also observed a downregulation of a-SMA gene
(Figure 7e) and protein expression in Smad3/ mice treated
with rapamycin (Figure 6). Rapamycin-induced inhibition of
a-SMA has been observed in experimental diabetic nephro-
pathy41 and in a model of ureteric obstruction.42 This could
be a direct effect of mTOR/p70 S6 kinase inhibition or a
downstream effect through b-catenin signaling.
In summary, in these experiments we describe a novel
in vivo model to explore the signaling pathways involved in
the complex tissue response to TGF-b1. The majority of
TGF-b1 responses do seem to be mediated by Smad3
signaling. Fibrosis and angiogenesis are significantly curtailed
in the Smad3/ mice. An attenuated EMT process is
observed in the Smad3/ mice with an increased expression
of a-SMA and a decrease in E-cadherin. Rapamycin almost
completely abrogated the EMT response in the Smad3/
mice while having minimal effect on the Smad3þ /þ mice.
This suggests that there are at least two parallel, interacting
pathways involved in TGF-b1-induced EMT. In the absence
of Smad3, Akt activation and downstream b-catenin seem to
be important mediators of EMT. b-catenin expression and
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Figure 6 |Rapamycin inhibits epithelial-to-mesenchymal transition in Smad3/ mice. Sections of parietal peritoneum in Smad3/
mice at 7 days after treatment with (a–c) adenovirus expressing transforming growth factor-b1 (AdTGF-b1) and vehicle or (d–f) AdTGF-b1
and rapamycin. Sections were stained for (a, d) cytokeratin and (b, e) a-smooth muscle actin (a-SMA) with (c, f) 4,6-diamidino-2-
phenylindole (DAPI) counterstaining. (a–c) Smad3/ mice treated with intraperitoneal AdTGF-b1 and with vehicle by gavage showed
epithelial-to-mesenchymal transition (EMT) with evidence of invasive mesothelial cells staining for both cytokeratin and a-SMA (thin arrows)
along with mesothelial cells without evidence of EMT (thick arrows). (d–f) Smad3/ mice treated with AdTGF-b1 and rapamycin showed a
significantly reduced EMT response with only occasional dual-labeled cells observed (thin arrows) with no evidence of invasion. Original
magnification 200. (g) The number of dual-labeled cells per millimeter of peritoneum were quantified. Rapamycin had little effect on EMT
in Smad3þ /þ mice but significantly decreased EMT in Smad3/ mice.
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nuclear localization was inhibited by rapamycin. Further
work is required to delineate the exact mechanism of the
Smad3/PI3K pathway interaction, and the mechanism of
rapamycin inhibition of b-catenin.
MATERIALS AND METHODS
Recombinant adenoviruses
The construction of the adenovirus vectors AdTGF-b143 has been
previously described. AdTGF-b1 was created with TGF-b1 cDNA
mutated at residues 223 and 225, so that the transgene product
does not bind to the latency-associated protein and is therefore
biologically active. AdVEGF was created from the human splice
variant cDNA VEGF165 (gift from Dr D. Anthony, University of
Oxford, UK). A null adenovirus (AdDL) was used for control.
Animal studies
Smad3/ mice were generously provided by Dr A. Roberts. These
mice were generated by removal of exon 8 of the Smad3 gene in
the mice of background 127SV/EV  C57BL/6 as per Yang et al.39
Animals were treated in accordance with the guideline of the
Canadian Council on Animal Care. Smad3/ and littermate
Smad3þ /þ mice were infected with AdTGF-b1, AdVEGF, or AdDL
at a dose of 1.5 108 plaque-forming units diluted in 100 ml in
phosphate-buffered saline by intraperitoneal injection, and groups
of 5–7 animals were killed on days 4, 7, 14, and 21 after infection.
Before the mice were killed, 5ml of 4.25% Dianeal (Baxter
Healthcare, McGaw Park, IL, USA) was administered by intra-
peritoneal injection and then recovered at the time of killing. The
entire anterior abdominal wall was removed and half was taken for
histology and half for RNA extraction. Omental tissue was taken
and frozen in liquid nitrogen for protein extraction. Rapamycin
(generously provided by Wyeth, Markham, ON, Canada) or vehicle
was administered by oral gavage starting on day 3 and continuing
daily until day 7 at a dose of 2.5mg/kg.
Immunohistochemical analysis
Paraffin-embedded tissues of anterior abdominal wall were
sectioned and immunohistochemical analysis was performed using
von-Willebrand factor-related antigen (Dako, Carpenteria, CA,
USA). Peritoneum-associated blood vessels and submesothelial
thickness of the peritoneum were analyzed using Northern Eclipse
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Figure 7 |Protein was extracted from peritoneal tissues and
analyzed for p-Akt, glycogen synthase kinase (GSK)-3b, and
b-catenin expression. (a) Representative western blots. (b) p-Akt/
Akt was upregulated by transforming growth factor-b1 (TGF-b1),
which was more evident in Smad3/ mice. (c) pGSK-3b/GSK-3b
was increased in the Smad3/ mice treated with rapamycin
(Rapa). (d) b-catenin total protein concentration was increased
non-significantly in Smad3/ treated with adenovirus expressing
TGF-b1 (AdTGF-b1) and this effect was reversed by rapamycin.
(e) a-smooth muscle actin (a-SMA) gene expression was found
to be significantly inhibited by rapamycin.
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Figure 8 |Anterior abdominal wall sections were stained
for b-catenin (green) and counterstained with 4,6-diamidino-
2-phenylindole (DAPI; blue). (a, b) Smad3/ mice treated with
adenovirus expressing transforming growth factor-b1 (AdTGF-b1)
and vehicle show increased b-catenin expression in the peritoneal
tissues with evidence of both cytoplasmic and nuclear staining
(arrows). (c, d) Smad3/mice treated with AdTGF-b1 and rapamycin
(Rapa) show minimal b-catenin staining and no evidence of nuclear
localization. (e, f) A similar pattern is observed in Smadþ /þ mice
treated with control adenovirus (AdDL) and vehicle. (g, h) Smadþ /þ
mice treated with AdTGF-b1 and vehicle show increased b-catenin
expression with evidence of nuclear localization (arrow).
(i, j) b-catenin expression is present in Smad3þ /þ mice treated
with AdTGF-b1 (arrow), but nuclear localization seems to be
inhibited by treatment with rapamycin.
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image analysis software (Empix Imaging, Mississauga, ON, Canada).
Sections were stained for a-SMA (Dako) followed by a secondary
rabbit anti-mouse antibody labeled with Texas Red (Molecular
Probes, Eugene, OR, USA) and fluorescein isothiocyanate-conjugated
anti-cytokeratin (Sigma Chemicals, Oakville, ON, Canada). b-catenin
was assessed in formalin-fixed tissue using b-catenin antibody
(Cell Signaling Technology, Inc, MA, USA) followed by a secondary
fluorescein isothiocyanate-labeled antibody (Jackson Immuno-
Research, West Grove, PA, USA). Sections were also stained with
1% picrosirius red stain (Sigma). These sections were viewed under
polarized light and digitized images were taken. Using Northern
Eclipse software, relative orange–red or green birefringent areas
were calculated as a percentage of the total submesothelial tissue.
Previous studies have suggested that green birefringent areas repre-
sent type III collagen and is indicative of newly deposited collagen.26
Quantitative polymerase chain reaction
mRNA was extracted from the peritoneum of the killed animals
by immersing the parietal peritoneal surface in Trizol reagent
(Invitrogen, Burlington, Ontario, Canada) for 20min. RNA was
extracted from Trizol according to the manufacturer’s instruction.
RNA (1mg) was then reverse-transcribed using the standard
protocol (Invitrogen). Quantitative real-time polymerase chain
reaction for plasminogen activator inhibitor 1, VEGF, a-SMA, and
SNAIL was performed on mRNA using an ABI Prism 7700 Sequence
Detector (Applied Biosystems, Foster City, CA, USA). Glyceralde-
hyde-3-phosphate dehydrogenase was used as housekeeping gene.
Protein analysis
Protein analysis was carried out using western blot for E-cadherin
(BD Biosciences, Mississauga, ON, Canada), pAkt (Cell Signaling
Technology, MA, USA; specific for Ser 473 phosphorylation), total
Akt (Cell Signaling), GSK-3b, pGSK-3b (Cell Signaling; specific for
Ser 9 phosphorylation), b-catenin (Cell Signaling), and b-actin
(Sigma). Band density was measured using Scion Image Software
(Scion, Frederick, MD, USA).
Statistical analysis
We did not identify any substantial differences between Smad3/
and Smad3þ /þ animals treated with the control adenovirus. For
the purposes of data analysis, these two groups were combined.
Differences between groups were compared using analysis of
variance with Bonferroni’s post hoc analysis.
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